Nobelpharma Competitors and Similar CompaniesClear all

Nobelpharma's competitors and similar companies include Oasis Medical, Iconovo, Kaken Pharmaceutical and Cosmo Pharmaceuticals.

	Nobelpharma Nobelpharma (ノーベルファーマ) is a pharmaceutical company that is engaged in the research and development of medicines and medical devices.	Oasis Medical OASIS Medical is a company that specializes in eye care solutions.	Iconovo Iconovo is a company that offers the development of inhalation products: inhaler devices and dry powder formulations.	Kaken Pharmaceutical Kaken Pharmaceutical is a company providing pharmaceuticals and medical devices in the orthopedics and dermatology fields.	Cosmo Pharmaceuticals Cosmo Pharmaceuticals is a company that focuses on solutions in the areas of astroenterology and endoscopy.
Founding Date	Founding Date 2003	Founding Date 1987	Founding Date 2013	Founding Date 1948	Founding Date 1997
Type	Type Private	Type Private	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development medical devices pharma	Tags Healthcare biotech drug development medical devices pharma	Tags Healthcare biotech drug development medical devices pharma	Tags Healthcare biotech drug development medical devices pharma	Tags Healthcare biotech drug development medical devices pharma
Locations	Locations Chuo City, JP HQ	Locations Glendora, US HQ San Dimas, US	Locations Lund, SE HQ	Locations Bunkyo City, JP HQ	Locations Dublin, IE HQ
Employees	Employees 269	Employees 14816% increase	Employees 28	Employees 1,135	Employees 339
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 8.1 m	Valuation ($) 961.7 m	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) kr7.1m (FY, 2023)	Revenue (est.) ¥72b (FY, 2024)	Revenue (est.) €92.8m (FY, 2023)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods kr10.5m (FY, 2023)	Cost of goods ¥31.1b (FY, 2024)	Cost of goods €21.8m (FY, 2023)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit kr4.7m (FY, 2023)	Gross profit ¥41b (FY, 2024)	Gross profit €72.5m (FY, 2023)
Net income	Net income N/A	Net income N/A	Net income (kr45.9m) (FY, 2023)	Net income ¥8b (FY, 2024)	Net income (€4.7m) (FY, 2023)